Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016.
Brighton
Vaccine Adverse Event Reporting System
adverse event
anaphylaxis
epidemiology
hypersensitivity
vaccine
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
08
05
2018
revised:
07
12
2018
accepted:
24
12
2018
pubmed:
18
1
2019
medline:
24
4
2020
entrez:
18
1
2019
Statut:
ppublish
Résumé
Anaphylaxis, a rare and potentially life-threatening hypersensitivity reaction, can occur after vaccination. We sought to describe reports of anaphylaxis after vaccination made to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016. We identified domestic reports of anaphylaxis within VAERS using a combination of Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed a descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given. We reviewed all serious reports and all nonserious reports with available medical records to determine if they met the Brighton Collaboration case definition for anaphylaxis or received a physician's diagnosis. During the analytic period, VAERS received 467,960 total reports; 828 met the Brighton Collaboration case definition or received a physician's diagnosis of anaphylaxis: 654 (79%) were classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged less than 19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 reports in persons aged 19 years or greater, 80% were female, and influenza vaccines were most frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. We identified 8 deaths, 4 among persons with no history of hypersensitivity. Anaphylaxis after vaccination is rare in the United States and can occur among persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious complications, including death, can occur.
Sections du résumé
BACKGROUND
Anaphylaxis, a rare and potentially life-threatening hypersensitivity reaction, can occur after vaccination.
OBJECTIVE
We sought to describe reports of anaphylaxis after vaccination made to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016.
METHODS
We identified domestic reports of anaphylaxis within VAERS using a combination of Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed a descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given. We reviewed all serious reports and all nonserious reports with available medical records to determine if they met the Brighton Collaboration case definition for anaphylaxis or received a physician's diagnosis.
RESULTS
During the analytic period, VAERS received 467,960 total reports; 828 met the Brighton Collaboration case definition or received a physician's diagnosis of anaphylaxis: 654 (79%) were classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged less than 19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 reports in persons aged 19 years or greater, 80% were female, and influenza vaccines were most frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. We identified 8 deaths, 4 among persons with no history of hypersensitivity.
CONCLUSION
Anaphylaxis after vaccination is rare in the United States and can occur among persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious complications, including death, can occur.
Identifiants
pubmed: 30654049
pii: S0091-6749(19)30020-X
doi: 10.1016/j.jaci.2018.12.1003
pmc: PMC6580415
mid: NIHMS1032255
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1465-1473Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
MMWR Morb Mortal Wkly Rep. 1999 Jul 16;48(27):577-81
pubmed: 10428095
MMWR Morb Mortal Wkly Rep. 1999 Nov 5;48(43):1007
pubmed: 10577495
Am J Respir Crit Care Med. 2000 Jul;162(1):68-74
pubmed: 10903222
Pediatr Infect Dis J. 2000 Dec;19(12):1127-34
pubmed: 11144371
J Allergy Clin Immunol. 2001 Nov;108(5):861-6
pubmed: 11692116
Arch Dis Child. 2002 Apr;86(4):236-9
pubmed: 11919093
Pediatrics. 2002 Dec;110(6):e71
pubmed: 12456938
Pediatrics. 2003 Oct;112(4):815-20
pubmed: 14523172
Pediatr Infect Dis J. 2004 Apr;23(4):287-94
pubmed: 15071280
J Eur Acad Dermatol Venereol. 2004 Sep;18(5):603-6
pubmed: 15324406
Vaccine. 2007 Aug 1;25(31):5675-84
pubmed: 17448577
Allergy. 2008 Jan;63(1):47-57
pubmed: 17822448
J Infect Dis. 2008 Mar 1;197 Suppl 2:S170-7
pubmed: 18419393
Clin Exp Allergy. 2011 Jul;41(7):923-38
pubmed: 21668816
Arch Dis Child. 2012 Jun;97(6):487-90
pubmed: 22275307
Clin Vaccine Immunol. 2013 Feb;20(2):211-7
pubmed: 23239804
J Allergy Clin Immunol. 2014 Dec;134(6):1318-1328.e7
pubmed: 25280385
J Allergy Clin Immunol. 2015 Apr;135(4):956-63.e1
pubmed: 25468198
J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):88-93
pubmed: 25577624
Vaccine. 2015 Mar 24;33(13):1602-7
pubmed: 25698493
Clin Infect Dis. 2015 Sep 15;61(6):980-7
pubmed: 26021988
J Investig Allergol Clin Immunol. 2015;25(3):163-75; quiz follow 174-5
pubmed: 26182682
Vaccine. 2015 Aug 26;33(36):4398-405
pubmed: 26209838
Ann Allergy Asthma Immunol. 2015 Oct;115(4):301-5
pubmed: 26256577
J Allergy Clin Immunol. 2016 Mar;137(3):868-78
pubmed: 26452420
MMWR Morb Mortal Wkly Rep. 2016 Feb 05;65(4):86-7
pubmed: 26845283
MMWR Morb Mortal Wkly Rep. 2016 Feb 05;65(4):88-90
pubmed: 26845417
J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):718-727.e1
pubmed: 27914816
Arch Dis Child. 1984 Oct;59(10):983-6
pubmed: 6541895
BMJ. 1998 May 9;316(7142):1442-5
pubmed: 9572760